Cadaveric Renal Transplantation in the Elderly
Cadaveric renal transplantation is now the accepted optimal therapy for end stage renal failure, since it provides, when successful, a quality of life considerably greater than that resulting from either haemodialysis (HD) or continuous ambulatory peritoneal dialysis (CAPD). Patient survival is, in most units, greater than 90% at 1 yr with concommitant graft survival for cadaveric donor transplantation at over 75%. Contributing to this increased success has been the more judicious use of immunosuppressive (IS) agents, greater clinical experience in the management of complications, better quality donor kidneys and more precise histocompatibility. Recently there has been a significant benefit from the use of a more effective and more specific IS agent in the form of Cyclosporin A (CYA). In addition, over the last three years combination IS therapy using triple therapy (1) or quadruple therapy with polyclonal or monoclonal antibodies has provided even better graft survival.
KeywordsGraft Survival Triple Therapy Cadaveric Donor Anti Thymocyte Globulin Quadruple Therapy
Unable to display preview. Download preview PDF.
- 1.Slapak, M., Geoghegan, T., Digard, N., Ahmed, K., Sharman, V.L., Crockett, R. Trans. Proc. XIX 2, 41–45, 1987Google Scholar
- 2.Digard, N., Geoghegan, T., Harris, K.R., and Slapak, M. Trans. Proc. XVI 1, 107–108, 1984.Google Scholar
- 3.Slapak, M., Thompson, F.C., Digard, N., Shell, T., Crockett, R., Ahmed, K. Nephrol. Dial. Transplant. 3, 96–97, 1988.Google Scholar
- 4.Belitsky, P., MacDonald, A.S., Gajewski, J., Boudreau, J., Bittesauermann, H., Cohen, A. Trans, proc. 19, 2096–2099, 1987.Google Scholar